Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
OlympiA
About the Trial
OlympiA randomized 1,836 patients with germline BRCA1 or BRCA2 mutations and high risk HER2 negative early breast cancer to adjuvant olaparib for a year or placebo. The PARP inhibitor reduced invasive disease events by 42 percent and death by 32 percent. The trial moved PARP inhibition from metastatic to curative settings and entrenched germline genetic testing in early breast cancer management. It also validated the synthetic lethality concept, tumor BRCA deficiency plus PARP blockade, in the curative setting. OlympiA exemplifies how germline genomics now personalizes adjuvant therapy decisions.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...